Opioid MME Calculator
Convert up to three prescribed opioid exposure lines to estimated morphine milligram equivalents per day using the CDC 2022 U.S. conversion table. The ledger shows every factor and keeps fentanyl’s mcg/hour unit visible.
Enter total daily exposure
For tablets or liquids, add the opioid ingredient taken in a full day—not acetaminophen, solution volume, or tablet count. For transdermal fentanyl, enter the patch delivery rate in mcg/hour.
Estimated total exposure
CDC advises clinicians to pause before increasing total dosage to 50 MME/day or more, carefully reassess benefits and risks, and add precautions when dosage reaches or exceeds that level. Risk exists below 50, and the number is not a rigid limit.
No methadone or transdermal fentanyl line is active. Still verify product, route, schedule, actual use, renal/hepatic status, other sedatives, and overdose history with the clinician and pharmacist.
What MME means—and what it does not
Morphine milligram equivalents provide a common scale for comparing the opioid component of different pain medicines. The number estimates how a total daily opioid amount relates to oral morphine using a published conversion factor. In the United States, clinicians, researchers, health systems, and payers may use MME to review exposure patterns and overdose risk at a population level.
MME does not measure a person’s pain, function, opioid tolerance, metabolism, current sedation, respiratory reserve, or likelihood of benefit. Two people with the same MME can have very different risks because of age, sleep apnea, lung disease, kidney or liver impairment, pregnancy, frailty, prior overdose, substance use disorder, genetics, concurrent benzodiazepines or alcohol, and whether the medicine was newly started.
Most importantly, MME is not a conversion prescription. The CDC table warns that equianalgesic estimates cannot account for individual pharmacokinetic variation or incomplete cross-tolerance. A replacement opioid is generally dosed substantially below a simplistic MME-equivalent amount under close clinical supervision. This tool never displays a replacement dose.
The ledger equation
Total MME/day = sum of all active lines
The demonstration contains hydrocodone 40 mg/day and oxycodone 10 mg/day. Hydrocodone uses factor 1.0, producing 40 MME/day. Oxycodone uses factor 1.5, producing 15 MME/day. The total is 55 MME/day. A zero codeine line contributes nothing.
For oral and other listed non-fentanyl products, enter milligrams of the opioid ingredient per day. If a prescription says hydrocodone 5 mg/acetaminophen 325 mg and four tablets are actually taken in a day, the opioid amount is 20 mg/day—not 1,300 mg, which is the acetaminophen amount. Confirm combination labels carefully to avoid a dangerous unit error.
Transdermal fentanyl is the exception in the table: its input is patch delivery rate in micrograms per hour, and the factor is 2.4. Do not convert mcg to mg before using this particular table. Heat, fever, damaged patches, timing, patch stacking, and opioid tolerance can materially affect safety; fentanyl patches are not for opioid-naive use.
CDC 2022 conversion factors used
| Opioid | Input unit | Factor | Essential limitation |
|---|---|---|---|
| Codeine | mg/day | 0.15 | Metabolic variation can change clinical response. |
| Fentanyl transdermal | mcg/hour | 2.4 | Patch absorption and the different unit demand particular caution. |
| Hydrocodone | mg/day | 1.0 | Count hydrocodone, not the nonopioid combination ingredient. |
| Hydromorphone | mg/day | 5.0 | A small milligram entry can yield substantial MME. |
| Methadone | mg/day | 4.7 | Long, variable half-life and delayed respiratory depression make conversion especially hazardous. |
| Morphine | mg/day | 1.0 | Route and formulation must match the source context. |
| Oxycodone | mg/day | 1.5 | Add immediate- and extended-release amounts taken in the same day. |
| Oxymorphone | mg/day | 3.0 | Do not infer an equivalent replacement dose. |
| Tapentadol | mg/day | 0.4 | CDC notes uncertainty about whether overdose risk scales like pure mu-agonists. |
| Tramadol | mg/day | 0.2 | Also has serotonin and norepinephrine effects not represented by MME. |
The CDC discontinued its older NDC-level oral MME file and identifies the conversion table in the 2022 Clinical Practice Guideline as its resource for MME factors. Product identity still requires an authoritative medication list, pharmacy record, FDA-approved label, and clinical reconciliation.
Why 50 MME/day is shown as a guidepost
MME is not zero risk
Common low starting range context
Pause and reassess
Higher observed overdose risk
Patient context controls
The CDC 2022 guideline tells clinicians to pause before increasing a total opioid dosage to 50 MME/day or more, carefully reassess evidence of individual benefits and risks, and use the smallest practical increase when an increase is warranted. At or above 50, it advises additional precautions such as increased follow-up and offering naloxone and overdose education to the patient and household members.
This is not a bright line between safe and unsafe. Overdose risk increases progressively, varies by patient, and exists at lower dosages. The guideline also cautions against treating recommendations as inflexible policy, rapidly tapering stable patients, or abruptly discontinuing opioids unless a life-threatening issue requires immediate action. The result banner therefore says “guidepost,” not “limit” or “maximum.”
A high total does not authorize an unplanned taper. A low total does not authorize adding sedatives, drinking alcohol, driving while impaired, taking extra doses, or sharing medication. The prescriber and pharmacist must evaluate the entire regimen.
Products and uses deliberately excluded
Buprenorphine products are not included because the CDC pain table does not assign them these MME factors; partial agonist pharmacology and ceiling effects make a simple comparison misleading. The listed factors must not be applied to medication treatment for opioid use disorder. Methadone or buprenorphine used for OUD is managed under dedicated clinical protocols, not pain-dose browser arithmetic.
The ledger also excludes injectable, epidural, intrathecal, transmucosal, and other opioid routes not specified in the displayed CDC table. It cannot reconcile milliliters without drug concentration, “as needed” prescriptions without actual daily use, or a patch that was cut, overlapped, removed late, or exposed to heat. Ask a pharmacist to reconstruct uncertain exposure.
Illicitly manufactured fentanyl and unknown pills cannot be converted from appearance, street name, price, or reported weight. Their content may be unpredictable. Do not use this tool to plan nonmedical opioid use.
Use the number inside a safety review
Medication reconciliation should distinguish the maximum allowed prescription from actual daily exposure. A prescription written “one tablet every six hours as needed” describes a ceiling, not necessarily four doses every day. For prospective prescribing review, the clinician may calculate the maximum planned daily amount; for retrospective exposure review, document what was actually taken and the time interval.
Benzodiazepines, non-benzodiazepine sedative-hypnotics, muscle relaxants, gabapentinoids, alcohol, and other central nervous system depressants can increase sedation and respiratory risk. MME does not incorporate those interactions. Neither does it account for a person’s recent loss of tolerance after abstinence, incarceration, detoxification, hospitalization, or treatment.
Store opioids locked, never share them, and use an FDA- or community-recommended take-back option for unused medicine. Families should know where naloxone is kept and how to call emergency services.
Tapering and rotation require a clinical plan
Long-term opioid therapy creates physiologic dependence. Abrupt discontinuation or a rapid forced taper can cause withdrawal, uncontrolled pain, psychological distress, loss to care, and unsafe attempts to replace medication. The CDC recommends collaborative, patient-centered decisions and warns against rigid application of dosage thresholds.
When opioid rotation is clinically indicated, incomplete cross-tolerance is one reason the new drug is typically started substantially below the mathematical equianalgesic estimate. Methadone is particularly complex because analgesic duration, half-life, accumulation, drug interactions, and respiratory depression do not follow a simple linear relationship. Transdermal fentanyl has separate labeling and eligibility requirements.
The calculator offers no taper percentage, schedule, or replacement dose. Contact the prescriber before changing frequency, splitting an extended-release product, removing a patch, or compensating for a missed dose. If medication is unavailable or withdrawal is developing, seek timely professional help rather than improvising with another person’s medicine.
Frequently asked questions
Is 50 MME/day the maximum legal opioid dose?
No. It is a CDC clinical guidepost for pause, reassessment, and additional precautions, not a federal legal maximum or a line that separates safe from unsafe care.
Can I convert the total MME into an oxycodone dose?
No. CDC explicitly warns not to use MME to choose the dose when converting opioids. Incomplete cross-tolerance and patient variation can make that dangerous.
Why is a fentanyl patch entered in mcg/hour?
That is the unit used by the CDC conversion table and patch labeling. Do not enter patch strength as mg/day or multiply by 24 before applying the displayed factor.
Does MME include acetaminophen in a combination tablet?
No. Enter only the opioid ingredient. Acetaminophen has its own daily exposure and liver-toxicity limits that require separate review.
Why is buprenorphine absent?
The CDC pain table excludes it because partial-agonist pharmacology makes these simple MME factors inappropriate. OUD treatment dosing must never be handled with this calculator.
What should I do if the result seems unexpectedly high?
Do not stop medication suddenly. Recheck drug, route, unit, total daily amount, duplicate entries, and combination labels, then contact the prescriber or pharmacist promptly.
Related U.S. planning context
It does not determine prescription coverage, medical deductions, drug cost, or clinical eligibility.
References
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain—United States, 2022
- CDC: Opioid NDC and Oral MME Conversion File Update
- CDC: About Overdose Prevention
- U.S. Food and Drug Administration: Opioid Medications
- FDA: Where and How to Dispose of Unused Medicines
Educational exposure estimate only. Verify every medicine with a licensed prescriber and pharmacist. Call 911 for suspected overdose.